基于抗炎机制探讨甘麦大枣汤经方新用治疗帕金森病焦虑症的临床研究

注册号:

Registration number:

ChiCTR2300068573 

最近更新日期:

Date of Last Refreshed on:

2023-05-28 11:03:20 

注册时间:

Date of Registration:

2023-02-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于抗炎机制探讨甘麦大枣汤经方新用治疗帕金森病焦虑症的临床研究

Public title:

Clinical research on the Ganmaidazao Decoction Treating Anxiety in Parkinson's Disease based on the anti-inflammatory mechanism

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于抗炎机制探讨甘麦大枣汤经方新用治疗帕金森病焦虑症的临床研究

Scientific title:

Clinical research on the Ganmaidazao Decoction Treating Anxiety in Parkinson's Disease based on the anti-inflammatory mechanism

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

巫朝银 

研究负责人:

巫朝银 

Applicant:

Wu Chaoyin 

Study leader:

Wu Chaoyin 

申请注册联系人电话:

Applicant telephone:

+86 132 2663 5090

研究负责人电话:

Study leader's
telephone:

+86 132 2663 5090

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wuchaoyin1919@163.com

研究负责人电子邮件:

Study leader's E-mail:

wuchaoyin1919@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国广东省佛山市顺德区大良街道金沙大道12号

研究负责人通讯地址:

中国广东省佛山市顺德区大良街道金沙大道12号

Applicant address:

12 Jinsha Avenue, Daliang Street, Shunde District, Foshan, Guangdong, China

Study leader's address:

12 Jinsha Avenue, Daliang Street, Shunde District, Foshan, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州中医药大学顺德医院

Applicant's institution:

Shunde Hospital of Guangzhou University of Traditional Chinese Medicine

研究负责人所在单位:

广州中医药大学顺德医院

Affiliation of the Leader:

Shunde Hospital of Guangzhou University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2022034

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广州中医药大学顺德医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shunde Hospital of Guangzhou University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022-04-27 00:00:00

伦理委员会联系人:

庞雨

Contact Name of the ethic committee:

Pang Yu

伦理委员会联系地址:

中国广东省佛山市顺德区大良街道金沙大道12号

Contact Address of the ethic committee:

12 Jinsha Avenue, Daliang Street, Shunde District, Foshan, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 757 22322758

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州中医药大学顺德医院

Primary sponsor:

Shunde Hospital of Guangzhou University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

中国广东省佛山市顺德区大良街道金沙大道12号

Primary sponsor's address:

12 Jinsha Avenue, Daliang Street, Shunde District, Foshan, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

佛山

Country:

China

Province:

Guangdong

City:

Foshan

单位(医院):

广州中医药大学顺德医院

具体地址:

顺德区大良街道金沙大道12号

Institution
hospital:

Shunde Hospital of Guangzhou University of Traditional Chinese Medicine

Address:

12 Jinsha Avenue, Daliang Street, Shunde District

经费或物资来源:

广东省中医药局科研项目

Source(s) of funding:

Scientific research project of Guangdong Provincial Bureau of Traditional Chinese Medicine

研究疾病:

帕金森病焦虑症状  

Target disease:

Anxiety in Parkinson's disease

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

目的是发掘经方甘麦大枣汤新的临床应用,为APD 患者寻求有效、安全的治疗措施; 进一步, 研究其对APD 患者血清中MCP-1、CRP、TNF-α 影响, 探讨甘麦大枣汤是否通过抑制炎症因子, 发挥改善APD 的效果, 为后续深入挖掘此经方的应用奠定基础。  

Objectives of Study:

The purpose is to seek effective and safe treatment measures for APD patients, as well as explore the new clinical application of the Ganmaidazao decoction; furtherly, we will study the change on MCP-1, CRP and TNF-α in APD patients, exploreing whether Ganmaidazao decoction can improve APD by inhibiting inflammatory response, and establish the foundation for further exploration of the application.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 有较重大疾病者, 如脑外伤、严重的肝肾、血液、肿瘤、内分泌疾病等; 2. 同时参与其他药物临床试验者; 3. 有严重的精神疾病( 抑郁合并焦虑状态的患者除外); 4. 有酗酒史或药物滥用史者; 5. 糖尿病者或糖耐量异常者; 6. 对本研究使用的药物过敏者。

Exclusion criteria:

1. People with serious diseases, such as traumatic brain injury, severe liver and kidney, blood, tumor, endocrine diseases, etc.; 2. Participating in clinical trials of other drugs at the same time; 3. Severe mental illness (except for patients with depression and anxiety); 4. Those with a history of alcoholism or drug abuse; 5. Diabetes or impaired glucose tolerance; 6. Those who are allergic to the drugs used in this study.

研究实施时间:

Study execute time:

From 2023-01-01 00:00:00 To 2024-12-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-03-01 00:00:00 To 2024-06-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

在PD常规治疗的基础上口服甘麦大枣汤

干预措施代码:

Intervention:

On the basis of routine treatment of PD, oral Ganmai Dazao Decoction

Intervention code:

组别:

实验组

样本量:

30

Group:

Experimental group

Sample size:

干预措施:

在PD常规治疗的基础上口服安慰剂

干预措施代码:

Intervention:

Oral placebo on the basis of routine treatment for PD

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

佛山 

Country:

China

Province:

Guangdong

City:

Foshan

单位(医院):

广州中医药大学顺德医院 

单位级别:

三甲 

Institution
hospital:

Shunde Hospital of Guangzhou University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

汉密尔顿焦虑量表评分

指标类型:

主要指标

Outcome:

Hamilton Anxiety Scale score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

统一帕金森病评定量表Ⅲ评分

指标类型:

次要指标

Outcome:

Parkinson's Disease Rating Scale III score was unified

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

安全性指标

指标类型:

附加指标

Outcome:

Safety indicators

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 55 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

指定一名研究者采用SPSS 软件产生随机数列。

Randomization Procedure (please state who generates the random number sequence and by what method):

One investigator was assigned to generate random series using SPSS software.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2025年,中国知网

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2025, China Knowledge Network

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.病例记录表,2.电子采集和管理系统(Electronic Data Capture, EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2023-02-23 16:06:16